Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Ichor Medical Systems-The TriGrid® to be Used with a COVID-19 DNA Vaccine in Development by the Naval Medical Research Center

Ichor Medical Systems, Inc. announced today that its clinical stage TriGrid® Delivery System (TriGrid) is being utilized for delivery of a DNA vaccine targeting the spike protein of SARS-CoV-2, the virus which causes coronavirus disease 2019 (COVID-19), into non-human primates as part of a prime-boost vaccination strategy being developed by the Naval Medical Research Center (NMRC).

Ichor Medical Systems notes this collaboration builds on Ichor’s long-standing relationship with the Department of Defense (DoD) exploring the potential of electroporation-based delivery to increase the potency of a number of biodefense- and pandemic-related DNA vaccines.

DNA vaccines are a promising vaccine platform that are able to promote the generation of antigen-specific antibodies and T cells. However, the efficacy of DNA vaccines delivered by conventional injection has been hindered by poor delivery efficiency, resulting in suboptimal immune responses in clinical trials. Electroporation is a potent delivery method that uses brief electrical pulses to transiently alter cell membranes, facilitating entry of DNA vaccines into cells leading to robust immune responses.

Ichor’s proprietary TriGrid is an integrated and fully automated system for electroporation-mediated in vivo DNA administration, enabling total control of the site of injection, placement of electrodes, rate of agent administration, and timing of electroporation delivery. TriGrid has been tested in more than 30 human studies on four continents. Clinical trials results have indicated that TriGrid delivery of DNA vaccines drives immune responses in recipients, and randomized comparative studies have further demonstrated that the TriGrid device significantly enhances immune responses to DNA vaccines compared to conventional injection.

“DNA vaccines represent a robust platform for rapid and cost-effective COVID-19 vaccine development because they are relatively straightforward to design and manufacture and compatible with long-term storage,” said Bob Bernard, President and CEO of Ichor. “Because of its superior ability to enhance the potency of DNA vaccines, Ichor’s TriGrid is uniquely positioned to enable multiple partners developing DNA vaccines not only for COVID-19 but for a broad spectrum of infectious disease and cancer targets relevant to public health.”

The effort is in support of Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance Award, sponsored by the Department of the Navy, Naval Medical Logistics Command under NMLC Award #N626451920002. The Award was issued as a Cooperative Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and the Infectious Diseases Directorate, Naval Medical Research Center (IDD-NMRC). HJF is collaborating with IDD-NMRC to develop and implement scientific research efforts in an effort to develop protective vaccines and other countermeasures targeting the causative agents of malaria, travelers’ diarrhea, rickettsia pathogens, multi-drug resistant bacteria, and emerging viral diseases. HJF engaged Ichor Medical Systems, Inc. to assist in meeting the research and development needs.

Other industry-featured news items can be found here.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy